China · Delayed Price · Currency is CNY Sirio Pharma Statistics
Total Valuation
Sirio Pharma has a market cap or net worth of CNY 5.88 billion. The enterprise value is 6.88 billion.
| Market Cap | 5.88B |
| Enterprise Value | 6.88B |
Important Dates
The last earnings date was Friday, April 24, 2026.
| Earnings Date | Apr 24, 2026 |
| Ex-Dividend Date | May 27, 2025 |
Share Statistics
Sirio Pharma has 307.02 million shares outstanding. The number of shares has increased by 0.24% in one year.
| Current Share Class | 307.02M |
| Shares Outstanding | 307.02M |
| Shares Change (YoY) | +0.24% |
| Shares Change (QoQ) | -0.16% |
| Owned by Insiders (%) | 20.65% |
| Owned by Institutions (%) | 18.05% |
| Float | 112.20M |
Valuation Ratios
The trailing PE ratio is 42.88 and the forward PE ratio is 15.77.
| PE Ratio | 42.88 |
| Forward PE | 15.77 |
| PS Ratio | 1.36 |
| PB Ratio | 1.98 |
| P/TBV Ratio | 2.82 |
| P/FCF Ratio | 151.45 |
| P/OCF Ratio | 11.96 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.52, with an EV/FCF ratio of 177.26.
| EV / Earnings | 58.45 |
| EV / Sales | 1.62 |
| EV / EBITDA | 15.52 |
| EV / EBIT | 32.79 |
| EV / FCF | 177.26 |
Financial Position
The company has a current ratio of 1.85, with a Debt / Equity ratio of 0.61.
| Current Ratio | 1.85 |
| Quick Ratio | 1.27 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 6.79 |
| Debt / FCF | 46.59 |
| Interest Coverage | 2.19 |
Financial Efficiency
Return on equity (ROE) is 0.21% and return on invested capital (ROIC) is 10.00%.
| Return on Equity (ROE) | 0.21% |
| Return on Assets (ROA) | 2.48% |
| Return on Invested Capital (ROIC) | 10.00% |
| Return on Capital Employed (ROCE) | 4.86% |
| Weighted Average Cost of Capital (WACC) | 5.51% |
| Revenue Per Employee | 1.55M |
| Profits Per Employee | 42,434 |
| Employee Count | 2,776 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 6.11 |
Taxes
| Income Tax | -24.81M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.77% in the last 52 weeks. The beta is 0.29, so Sirio Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | -0.77% |
| 50-Day Moving Average | 20.45 |
| 200-Day Moving Average | 23.07 |
| Relative Strength Index (RSI) | 38.12 |
| Average Volume (20 Days) | 2,029,017 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sirio Pharma had revenue of CNY 4.31 billion and earned 117.80 million in profits. Earnings per share was 0.39.
| Revenue | 4.31B |
| Gross Profit | 1.23B |
| Operating Income | 224.76M |
| Pretax Income | -18.97M |
| Net Income | 117.80M |
| EBITDA | n/a |
| EBIT | 224.76M |
| Earnings Per Share (EPS) | 0.39 |
Balance Sheet
The company has 669.31 million in cash and 1.81 billion in debt, with a net cash position of -1.14 billion or -3.71 per share.
| Cash & Cash Equivalents | 669.31M |
| Total Debt | 1.81B |
| Net Cash | -1.14B |
| Net Cash Per Share | -3.71 |
| Equity (Book Value) | 2.97B |
| Book Value Per Share | 9.70 |
| Working Capital | 921.58M |
Cash Flow
In the last 12 months, operating cash flow was 491.66 million and capital expenditures -452.82 million, giving a free cash flow of 38.84 million.
| Operating Cash Flow | 491.66M |
| Capital Expenditures | -452.82M |
| Depreciation & Amortization | 154.40M |
| Net Borrowing | -40.38M |
| Free Cash Flow | 38.84M |
| FCF Per Share | 0.13 |
Margins
Gross margin is 28.50%, with operating and profit margins of 5.21% and 2.73%.
| Gross Margin | 28.50% |
| Operating Margin | 5.21% |
| Pretax Margin | -0.44% |
| Profit Margin | 2.73% |
| EBITDA Margin | n/a |
| EBIT Margin | 5.21% |
| FCF Margin | 0.90% |
Dividends & Yields
This stock pays an annual dividend of 0.13, which amounts to a dividend yield of 0.68%.
| Dividend Per Share | 0.13 |
| Dividend Yield | 0.68% |
| Dividend Growth (YoY) | -23.18% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 154.60% |
| Buyback Yield | -0.24% |
| Shareholder Yield | 0.44% |
| Earnings Yield | 2.00% |
| FCF Yield | 0.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 27, 2025. It was a forward split with a ratio of 1.3.
| Last Split Date | May 27, 2025 |
| Split Type | Forward |
| Split Ratio | 1.3 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |